No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDSX Biodesix
- 1.400
- +0.090+6.87%
Close May 3 16:00 ET
- 1.400
- 0.0000.00%
Post 16:04 ET
159.08MMarket Cap-2187P/E (TTM)
1.400High1.310Low151.01KVolume1.330Open1.310Pre Close203.72KTurnover0.33%Turnover RatioLossP/E (Static)113.63MShares2.21052wk High35.00P/B64.10MFloat Cap1.03052wk Low--Dividend TTM45.78MShs Float31.990Historical High--Div YieldTTM6.87%Amplitude0.955Historical Low1.349Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biodesix Initiated at Buy by Lake Street
Biodesix Initiated at Buy by Lake Street
Express News | Lake Street Initiates Coverage On Biodesix With Buy Rating, Announces Price Target of $3
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of
The Recent US$4.0m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Biodesix, Inc. (NASDAQ:BDSX)
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
Studies highlight advancements in technology to detect cell-free DNA and rapid turnaround time in a real-world clinical setting Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung
Top Midday Decliners
Semantix's (STIX) shares slumped nearly 45% intraday after the company said late Thursday that it notified the Nasdaq Stock Market of its decision to voluntarily delist its ordinary shares and warrant
Comments
$Biodesix(BDSX.US$ TEST CAN NOT SHORT MUST NOT BUY 🔊📢👹
ColumnsToday's pre-market stock movers: NFLX, NVAX, ASML, BBWI and more
Gainers:
In reaction to earnings/guidance:
• $Omnicom Group(OMC.US$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix(NFLX.US$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial(FULT.US$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories(ABT.US$ +0.6% (Ab...
In reaction to earnings/guidance:
• $Omnicom Group(OMC.US$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix(NFLX.US$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial(FULT.US$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories(ABT.US$ +0.6% (Ab...
19
2
$Biodesix(BDSX.US$
small float on market watch, is this a squeeze play? The chart has a lot of promise
small float on market watch, is this a squeeze play? The chart has a lot of promise
$Biodesix(BDSX.US$ this could break 1.56 again.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg